Muscular Dystrophy Trial, Recruiting NCT05020002 Sponsor: Massachusetts General Hospital Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Muscular Dystrophy Trial, Recruiting

NCT05020002
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2), either through genetic testing or based on symptoms — even if you haven't had genetic testing done.
  • You are a healthy person with no known muscular dystrophy (for comparison purposes in the study).
  • You are able to give your consent (or, for younger participants, give your agreement/assent) to take part in the study.
  • For a single sample collection (blood, urine, or similar): you are male or female, aged 5 years or older, with or without DM.
  • For repeated sample collections over time: you are male or female, aged 14 or older, and have DM1.
  • For sample collection that includes a muscle biopsy: you are male or female, aged between 18 and 65 years.

Who may not be able to join:

  • You have a history of a weakened immune system, a blood-clotting disorder, liver disease, kidney disease, HIV, or Hepatitis B or C.
  • You have taken blood-thinning or anti-clotting medications within the past 7 to 60 days before a blood draw or biopsy (confirm with trial site for exact timeframes).
  • You are currently using or dependent on drugs or alcohol in a way that could affect your recovery after a biopsy, in the opinion of the doctor performing the procedure.
  • You are pregnant, planning to become pregnant before a biopsy, or have a positive pregnancy test.
  • You are unwilling or unable to give written consent (or assent) to take part in the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thurman M. Wheeler, MD, Massachusetts General Hospital

Phone: 617-726-7506

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 December 2020
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Extracellular RNA splice variants in biofluids

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov